Ascendis Pharma A/S logo

ASND - Ascendis Pharma A/S Share Price

$139.13 -1.3  -1.0%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £5.11bn
Enterprise Value £4.58bn
Revenue £18.2m
Position in Universe 1022nd / 6415
Bullish
Bearish
Unlock ASND Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ASND Revenue Unlock ASND Revenue

Net Income

ASND Net Income Unlock ASND Revenue

Normalised EPS

ASND Normalised EPS Unlock ASND Revenue

PE Ratio Range

ASND PE Ratio Range Unlock ASND Revenue

Dividend Yield Range

ASND Dividend Yield Range Unlock ASND Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ASND EPS Forecasts Unlock ASND Revenue
Profile Summary

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated September 21, 2006
Public Since January 28, 2015
No. of Shareholders: n/a
No. of Employees: 216
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 47,739,647
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ASND Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ASND
Upcoming Events for ASND
Similar to ASND
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.